研究单位：[1]Stryker Neurovascular[2]Stryker (Beijing) Healthcare Products Co., Ltd[3]Xuanwu Hospital Capital Medical University,Beijing,China,100053[4]Beijing Tiantan Hospital, Capital Medical University,Beijing,China,100070[5]Peking University Third Hospital,Beijing,China,100191[6]Bethune First Hospital of Jilin University,Changchun,China,130021[7]First Affiliated Hospital of Kunming Medical University,Kunming,China,650032[8]Shanghai Fourth People's Hospital Affiliated To Tongji University,Shanghai,China,200434[9]South China Hospital of Shenzhen University,Shenzhen,China,518111[10]The Third Hospital of Hebei Medical University,Shijiazhuang,China,050051[11]Tangshan Workers' Hospital,Tangshan,China,063000[12]The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,China,710061[13]Xiangyang No.1 People's Hospital,Xiangyang,China,441000[14]Zhuhai People's Hospital,Zhuhai,China,519000
研究目的：
A prospective, multi-center, single-arm, open-label, observational, post-market clinical follow-up. The expected duration of the study is 8 years (including up to 5-years' follow-up). Each subject will be followed up per standard of care (SoC) at each study site.
